Literature DB >> 34979547

Two Cases of Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections Caused by the Omicron Variant (B.1.1.529 Lineage) in International Travelers to Japan.

Taketomo Maruki1, Noriko Iwamoto1, Kohei Kanda1, Nobumasa Okumura1, Gen Yamada1, Masahiro Ishikane1, Mugen Ujiie1, Masumichi Saito2, Tsuguto Fujimoto2, Tsutomu Kageyama2, Tomoya Saito2, Shinji Saito2, Tadaki Suzuki2, Norio Ohmagari1.   

Abstract

In November 2021, the World Health Organization designated a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern, Omicron (PANGO lineage B.1.1.529). We report on the first 2 cases of breakthrough coronavirus disease 2019 (COVID-19) caused by Omicron in Japan among international travelers returning from the country with undetected infection. The spread of infection by Omicron were considered.
© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  COVID-19; Omicron; SARS-CoV-2; spike mutation; variant of concern

Mesh：

Year:  2022        PMID： 34979547      PMCID： PMC8755371          DOI： 10.1093/cid/ciab1072

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   20.999


  5 in total

1.  Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.

Authors:  Koichi Furukawa; Lidya Handayani Tjan; Yukiya Kurahashi; Silvia Sutandhio; Mitsuhiro Nishimura; Jun Arii; Yasuko Mori
Journal:  JAMA Netw Open       Date:  2022-05-02

Review 2.  Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic.

Authors:  Rekha Khandia; Shailja Singhal; Taha Alqahtani; Mohammad Amjad Kamal; Nahed A El-Shall; Firzan Nainu; Perumal Arumugam Desingu; Kuldeep Dhama
Journal:  Environ Res       Date:  2022-01-29       Impact factor: 8.431

3.  Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron Variant-Infected Vaccinees.

Authors:  Kenichiro Takahashi; Masahiro Ishikane; Mugen Ujiie; Noriko Iwamoto; Nobumasa Okumura; Testsuro Sato; Maki Nagashima; Ataru Moriya; Michiyo Suzuki; Masayuki Hojo; Takayuki Kanno; Shinji Saito; Sho Miyamoto; Akira Ainai; Minoru Tobiume; Takeshi Arashiro; Tsuguto Fujimoto; Tomoya Saito; Masaya Yamato; Tadaki Suzuki; Norio Ohmagari
Journal:  Emerg Infect Dis       Date:  2022-03-15       Impact factor: 16.126

4.  Reduced neutralizing antibody response in naïve Covishield vaccinees against Omicron emphasizes booster vaccination.

Authors:  Pragya D Yadav; Gajanan N Sapkal; Rima R Sahay; Deepak Y Patil; Sachee Agrawal; Balkrishna Adsul; Srikanth Tripathy; Gururaj R Deshpande; Dimpal A Nyayanit; Anita M Shete; Manish Manraie; Sanjay Kumar; Jayanthi Shastri; Priya Abraham
Journal:  J Infect       Date:  2022-04-21       Impact factor: 38.637

Review 5.  SARS-CoV-2 Omicron and its current known unknowns: A narrative review.

Authors:  Trang Thi Bich Le; Tamilarasy Vasanthakumaran; Hau Nguyen Thi Hien; I-Chun Hung; Mai Ngoc Luu; Zeeshan Ali Khan; Nguyen Thanh An; Van Phu Tran; Wei Jun Lee; Jeza Muhamad Abdul Aziz; Tasnim Ali; Shyam Prakash Dumre; Nguyen Tien Huy
Journal:  Rev Med Virol       Date:  2022-09-23       Impact factor: 11.043
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.